

Cialis[®] (tadalafil) – First-time generic

- On September 27, 2018, <u>Teva launched</u> an <u>AB-rated</u> generic version of Eli Lilly's <u>Cialis (tadalafil)</u> tablets.
 - Teva was granted 180-days exclusivity.
 - Prasco has also launched an authorized generic of Cialis tablets.
- Cialis is indicated for the treatment of erectile dysfunction (ED); the signs and symptoms of benign prostatic hyperplasia (BPH); and ED and BPH.
- Tadalafil is also available as brand <u>Adcirca[®]</u>, which is approved for the treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability.
 - <u>Mylan launched</u> an <u>AB-rated</u> generic version of Adcirca in August 2018. Mylan was granted 180-days exclusivity.
- According to IQVIA, U.S. sales for Cialis were approximately \$1.93 billion for the 12 months ending In July 2018.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.